Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24468475 | 0.80 | POLB (0.39) | MAPK1 | |
| SCHEMBL29686086 | 0.80 | POLB (0.39) | MAPK1 | |
| SCHEMBL19523028 | 0.79 | ESR1 (0.46) | APLNRNTRK1HDAC6ESR1ESR2 | |
| SCHEMBL14472465 | 0.77 | APLNR (0.46) | APLNRNTRK1HDAC6ESR1ESR2 | |
| SCHEMBL22105074 | 0.77 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL31392878 | 0.77 | APLNR (0.50) | APLNRESR1ESR2HRH1KCNH2 | |
| SCHEMBL18596819 | 0.77 | APLNR (0.46) | APLNRNTRK1HDAC6ESR1ESR2 | |
| SCHEMBL22585597 | 0.77 | APLNR (0.50) | APLNRESR1ESR2HRH1KCNH2 | |
| SCHEMBL31489711 | 0.77 | APLNR (0.50) | APLNRESR1ESR2HRH1KCNH2 | |
| SCHEMBL30218199 | 0.77 | APLNR (0.50) | APLNRESR1ESR2HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE12 | APLNR 2541/4885NTRK1 2464/4885HDAC6 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.